Primary gastric mucosa associated lymphoid tissue lymphoma: clinical data predicted treatment outcome

World J Gastroenterol. 2008 Apr 21;14(15):2388-93. doi: 10.3748/wjg.14.2388.

Abstract

Aim: To determine clinical characteristics and treatment outcome of gastric lymphoma after chemotherapy and immuno-chemotherapy.

Methods: Thirty four patients with primary gastric mucosa associated lymphoid tissue (MALT) lymphoma (Ann Arbor stages I to IV) were enrolled. All had upper gastric endoscopy, abdominal ultrasonography, CT and H pylori status assessment (histology and serology). After anti-H pylori treatment and initial chemotherapy, patients were re-examined every 4 mo.

Results: Histological regression of the lymphoma was complete in 22/34 (64.7%) and partial in 9 (26.5%) patients. Median follow up time for these 31 responders was 60 mo (range 48-120). No regression was noted in 3 patients. Among the 25 (73.5%) H pylori positive patients, the eradication rate was 100%.

Conclusion: Using univariate analysis, predictive factors for overall survival were international prognostic index (IPI) score, hemoglobin level, erythrocyte sedimentation rate (ESR), and platelet numbers (P < 0.005). In addition to this, Cox proportion hazard model differentiate IPI score, ESR, and platelets as predictors of survival.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Blood Sedimentation
  • Female
  • Gastric Mucosa / microbiology
  • Gastric Mucosa / pathology*
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / isolation & purification
  • Hemoglobins / analysis
  • Humans
  • Kaplan-Meier Estimate
  • Lymphoma, B-Cell, Marginal Zone / blood
  • Lymphoma, B-Cell, Marginal Zone / drug therapy*
  • Lymphoma, B-Cell, Marginal Zone / microbiology
  • Lymphoma, B-Cell, Marginal Zone / mortality
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Patient Selection
  • Platelet Count
  • Proportional Hazards Models
  • Risk Assessment
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Hemoglobins